Lonza upgrades growth model as Lonza Group stock nears EUR 655.90 high

Published on 10/16/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza targets 10 to 13 percent growth and high-thirties margins. Lonza Group stock costs EUR 651.90 on October 16, 2026, below its EUR 655.90 high.

Growth targets and operating progress

Lonza set a 10 to 13 percent organic sales growth model on October 14, 2026.
H1 2026 sales reached CHF 3.4 billion with 16.0 percent constant-currency growth.
Lonza Group stock was trading at EUR 651.90 at 9:46 a.m. CEST at Lang & Schwarz on October 16, 2026, with a 52-week high of EUR 655.90.

Fotorealistische Reinraum-Bioreaktor-Halle mit glänzenden Edelstahltanks und steriler LED-Beleuchtung — Lonza CH0013841017 zeigt Reinraum Bioreaktor Halle mit Edelstahl Tanks steriler LED Beleuchtung, Illustration mit AI erstellt.

Lonza Group (ISIN CH0013841017) was trading at EUR 651.90 in pre-market dealings at Lang & Schwarz on October 16, 2026, at 9:46 a.m. CEST. The company raised its medium-term organic growth model to 10 to 13 percent and lifted its ambition for the CORE EBITDA margin to the high-thirties range, according to Lonza on October 14, 2026.

Targets move beyond 2026

Lonza also confirmed its full-year 2026 outlook of 11 to 12 percent constant-currency sales growth and a CORE EBITDA margin of 33 to 34 percent. Its third-quarter performance was in line with expectations across all business platforms, giving the new medium-term framework an operating base rather than making it a purely longer-term ambition.

The margin target is the sharper change for investors. Lonza expects CORE EBITDA growth to outpace sales growth, while its medium-term return on invested capital ambition is two to three times weighted average cost of capital, as stated in the October 14 release.

Three dated operating steps

On July 22, 2026, Lonza reported H1 sales of CHF 3.4 billion, up 16.0 percent at constant exchange rates, and CORE EBITDA of CHF 1.2 billion, up 27.4 percent, according to Lonza. On October 12, 2026, it expanded its dual-payload antibody-drug conjugate offering through exclusive access to Qurient CDK7 inhibitors, according to Lonza. The October 14, 2026 growth-model upgrade and Q3 update then set the latest operating reference.

What does the margin target mean?

The new range points to a wider profitability ambition than the 33 to 34 percent margin expected for 2026. Lonza links the improvement to maturing growth projects, better asset utilization, commercial execution and tighter capital expenditure discipline. The company also expects its pure-play contract development and manufacturing organization structure to support growth after the planned Capsules and Health Ingredients divestment.

Next date and stock context

The next company date listed for Lonza Group is January 27, 2027, for a quarterly update, according to wallstreetONLINE. The euro quote is EUR 4.00 below the cited 52-week high of EUR 655.90, a gap of 0.61 percent.

Stock near its yearly high

Lonza's operating story now combines a fresh medium-term growth target with a current full-year margin range. The share price is also close to its 52-week high, leaving execution against the 2026 outlook and the margin path as the central measurable questions.

Lonza Group stock was trading at EUR 651.90 at Lang & Schwarz on October 16, 2026 at 9:46 a.m. CEST.